Company Description
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The fi...
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
Valuation
Price to Book Ratio
0.30
Enterprise Value to EBITDA
1.00
Efficiency
Liquidity
Current Ratio
11.80
Quick Ratio
11.80
Cash Ratio
11.07
Profitability
Return on Assets
-33.24
Return on Equity
-35.74
Return on Total Capital
-35.82
Capital Structure
Total Debt to Total Assets
0.15
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Mr. Martin A. Lehr | 37 | 2015 | Chief Executive Officer & Director |
| Ms. Jennifer Minai-Azary | 44 | 2021 | Chief Financial Officer |
| Dr. Tarek Sahmoud | 60 | - | Chief Medical Officer |
| Dr. Evan G. Dick | 69 | - | Senior Vice President-Research & Development |
| Dr. Felix Kim | - | 2015 | Advisor |
Insider Actions
| 02/21/2023 |
Martin A. Lehr Chief Executive Officer; Director |
5,823 | Acquisition at $0.84 per share. | 4,891 |
| 02/13/2023 |
Martin A. Lehr Chief Executive Officer; Director |
5,606 | Acquisition at $0.87 per share. | 4,877 |
| 02/06/2023 |
Martin A. Lehr Chief Executive Officer; Director |
5,040 | Acquisition at $0.97 per share. | 4,888 |
| 01/30/2023 |
Martin A. Lehr Chief Executive Officer; Director |
7,027 | Acquisition at $0.7 per share. | 4,918 |
| 01/23/2023 |
Martin A. Lehr Chief Executive Officer; Director |
6,839 | Acquisition at $0.72 per share. | 4,924 |
| 01/17/2023 |
Martin A. Lehr Chief Executive Officer; Director |
6,783 | Acquisition at $0.74 per share. | 5,019 |
| 12/16/2022 |
Martin A. Lehr Chief Executive Officer; Director |
20,000 | Acquisition at $0.74 per share. | 14,800 |
| 12/16/2022 |
Jennifer Minai-Azary Chief Financial Officer |
25,000 | Acquisition at $0.74 per share. | 18,500 |
| 12/09/2022 |
Alex Levit Chief Legal Officer, Corp. Sec |
6,000 | Acquisition at $0.85 per share. | 5,100 |
| 08/19/2022 |
Martin A. Lehr Chief Executive Officer; Director |
13,000 | Acquisition at $1.85 per share. | 24,050 |
| 08/17/2022 |
Jennifer Minai-Azary Chief Financial Officer |
15,000 | Acquisition at $1.8 per share. | 27,000 |
MarketWatch News on CNTX
-
Friday's IPOs All Priced on the Low Side. Here's How the Stocks Did.
- Barron's Online
-
Bitcoin Miner Stronghold Stock Pops 52% in First Day of Trading
- Barron's Online
Other News on CNTX
-
10-Q: CONTEXT THERAPEUTICS INC.
- Edgar Online - (EDG = 10Q, 10K)
-
10-K: CONTEXT THERAPEUTICS INC.
- Edgar Online - (EDG = 10Q, 10K)
-
10-Q: CONTEXT THERAPEUTICS INC.
- Edgar Online - (EDG = 10Q, 10K)
-
10-Q: CONTEXT THERAPEUTICS INC.
- Edgar Online - (EDG = 10Q, 10K)
